UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike

The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.